Small molecule protein kinase inhibitors approved by regulatory agencies outside of the United States
Owing to genetic alterations and overexpression, the dysregulation of protein kinases plays a significant role in the pathogenesis of many autoimmune and neoplastic disorders and protein kinase antagonists have become an important drug target. Although the efficacy of imatinib in the treatment of ch...
Saved in:
Main Author: | Robert Roskoski Jr (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
by: Robert Roskoski, Jr
Published: (2024) -
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
by: Robert Roskoski, Jr
Published: (2024) -
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
by: Robert Roskoski, Jr
Published: (2023) -
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis
by: Robert Roskoski, Jr
Published: (2023) -
Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas
by: Robert Roskoski, Jr
Published: (2024)